A radiologist in a district general hospital reads a chest X-ray flagged as low risk by the triage algorithm sitting quietly behind her workstation. She agrees with it, signs it off, and moves to the next case in a queue that never seems to shorten. Months later, the patient returns with advanced disease that the software had missed and she had not independently caught. This is not a hypothetical anymore. The first clinical negligence claims involving artificial intelligence have now been formally lodged against NHS bodies, and they arrive at a moment when the health service has spent three years being told that AI is the tool that will finally bend the productivity curve.

The claims themselves are narrow in scope, concentrated in diagnostic imaging and risk-prediction tools that have moved from pilot schemes into routine workflow faster than the legal architecture around them has matured. But the questions they raise are structural rather than incidental. English clinical negligence law was built around a simple premise: a clinician exercises judgement, and that judgement can be measured against the standard of a reasonably competent peer. It was not built for a scenario in which the clinician's judgement is shaped, and sometimes overridden in practice if not in principle, by a proprietary model whose reasoning is not fully visible to the person relying on it.

This is where the claims become interesting for anyone running a trust rather than reporting on one. The Medical Protection Society and others have been warning for some time that current product liability rules leave clinicians and NHS bodies holding the risk that they should, in fairness, sit partly with the developers who built and marketed the software. A device manufacturer selling a faulty infusion pump faces consumer protection law. A company selling a diagnostic algorithm that systematically underweights a subtle nodule sits in murkier territory, protected in part by the framing of software as a decision-support tool rather than a medical device making the decision. NHS Resolution has issued guidance on indemnity and incident reporting, but guidance is not the same as settled case law, and settled case law is precisely what these first claims will begin to produce.

For NHS leaders the timing is awkward. Integrated care boards are under instruction to expand AI-assisted diagnostics as part of the productivity push that ministers have made central to the health service's recovery plan, at the same time as trusts are absorbing workforce shortages that make independent double-checking of every algorithmic output practically impossible. Radiology departments in particular have leaned on AI triage precisely because there are not enough radiologists to read every scan at the pace demand requires. A ruling that assigns greater liability to trusts for outputs they did not design and cannot fully audit would not stop that reliance, because the workforce gap is real, but it would raise the cost and caution attached to it considerably.

There is a genuine risk of overcorrection here. If liability settles heavily on clinicians and trusts, the rational response is defensive medicine: more repeat scans, more second opinions sought purely to create a paper trail, more hesitation before deploying tools that could otherwise ease pressure on overstretched services. That outcome would be a poor trade for patients, who benefit when triage tools catch what tired eyes miss at two in the morning. If liability instead extends properly to the companies building these systems, the pressure shifts to procurement and regulation, forcing life sciences firms to accept a share of clinical risk they have so far been able to avoid by classifying their products as advisory.

Neither outcome is guaranteed, and the claims now working through the system will not resolve the question quickly. What they have done is force it into the open. The NHS adopted AI diagnostics under the assumption that the legal framework would eventually catch up with the technology. That assumption is now being tested in court, not in policy papers, and the answer will do more to shape the pace of clinical AI adoption than any government strategy document has managed so far.

‍